Mesothelioma Research & Clinical Trials Listed below are the current clinical trials that are actively recruiting volunteers to help fight Mesothelioma and relieve its related illnesses. Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma Alimta plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma Active Symptom Control in Treating Patients With Malignant Pleural Mesothelioma EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Intraperitoneal or Pleural Cancer Pemetrexed Disodium and Gemcitabine in Treating Patients With Malignant Mesothelioma ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Malignant Mesothelioma ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma Neoadjuvant Pemetrexed Disodium and Cisplatin Followed by Surgery and Radiation Therapy in Treating Pleural Mesothelioma Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Experimental Drug SS1(dsFv)-PE38 to Treat Cancer Treatment of Peritoneal Cancer with Surgery, Perfused Heated Cisplatin, and Chemotherapy Study of Gene Induction Mediated in Patients with Pulmonary and Pleural Malignancies Study of Decitabine in Preventing Tumor Growth Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Alanosine in Treating Patients With Cancer PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Most clinical trials are designated as phase I, II, or III, based on the type of questions that study is seeking to answer: In Phase I clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety. In Phase III studies, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.